Muraro, Paolo A;
Mariottini, Alice;
Greco, Raffaella;
Burman, Joachim;
Iacobaeus, Ellen;
Inglese, Matilde;
Snowden, John A;
... ECTRIMS Focused Workshop HSCT, Yolanda; + view all
(2025)
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.
Nature Reviews Neurology
10.1038/s41582-024-01050-x.
(In press).
![[thumbnail of NRNEUROL-23-357_accepted.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
NRNEUROL-23-357_accepted.pdf - Accepted Version Access restricted to UCL open access staff until 16 July 2025. Download (811kB) |
Abstract
Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for relapsing forms of multiple sclerosis (MS) that are refractory to disease-modifying therapy (DMT). AHSCT after failure of high-efficacy DMT in aggressive forms of relapsing-remitting MS is a generally accepted indication, yet the optimal placement of this approach in the treatment sequence is not universally agreed upon. Uncertainties also remain with respect to other indications, such as in rapidly evolving, severe, treatment-naive MS, progressive MS, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, treatment and monitoring protocols, rehabilitation and other supportive care before and after AHSCT need to be optimized. To address these issues, we convened a European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop in partnership with the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party, in which evidence and key questions were presented and discussed by experts in these diseases and in AHSCT. Based on the workshop output and subsequent written interactions, this Consensus Statement provides practical guidance and recommendations on the use of AHSCT in MS and NMOSD. Recommendations are based on the available evidence, or on consensus when evidence was insufficient. We summarize the key evidence, report the final recommendations, and identify areas for further research.
| Type: | Article |
|---|---|
| Title: | Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT |
| Location: | England |
| DOI: | 10.1038/s41582-024-01050-x |
| Publisher version: | https://doi.org/10.1038/s41582-024-01050-x |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | AUTOIMMUNE-DISEASES, BLOOD, BONE-MARROW-TRANSPLANTATION, Clinical Neurology, CONDITIONING REGIMEN, DISEASE-MODIFYING THERAPY, DOSE IMMUNOSUPPRESSIVE THERAPY, EUROPEAN CONFERENCE, IRRADIATION, Life Sciences & Biomedicine, Neurosciences & Neurology, Science & Technology, SCT, WORKING PARTY |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neuroinflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10204958 |
Archive Staff Only
 |
View Item |
